Umbralisib治疗复发或难治性惰性淋巴瘤的IIb期研究
这项多队列开放标签IIb期研究评估了双重PI3Kδ/CK1ε抑制剂Umbralisib在208例复发或难治性边缘区淋巴瘤、滤泡性淋巴瘤或小淋巴细胞淋巴瘤患者中的疗效与安全性。结果显示总缓解率为47.1%,86.4%的患者肿瘤缩小,安全性总体可控,因不良事件停药率为15.4%。
要点
- Umbralisib在经重度治疗的复发/难治性惰性淋巴瘤中总缓解率达47.1%。
- 滤泡性淋巴瘤中位无进展生存期为10.6个月,小淋巴细胞淋巴瘤为20.9个月。
- ≥3级治疗中出现的不良事件发生率为53.4%,因不良事件停药率15.4%。
核心结论
- Umbralisib在经重度治疗的复发或难治性惰性非霍奇金淋巴瘤患者中显示出有临床意义的抗肿瘤活性。
- 安全性总体可控,免疫介导毒性和因不良事件停药的发生率相对较低。
研究设计与样本
- 多队列、开放标签、IIb期研究,纳入208例复发或难治性边缘区淋巴瘤、滤泡性淋巴瘤或小淋巴细胞淋巴瘤患者。
- 患者接受Umbralisib 800 mg口服每日一次,直至疾病进展、不可接受毒性或退出研究。
- 主要终点为总缓解率,次要终点包括起效时间、缓解持续时间、无进展生存期和安全性。
主要发现
- 中位随访时间:疗效分析27.7个月,安全性分析21.4个月。
- 总缓解率为47.1%,86.4%的患者出现肿瘤缩小。
- 中位起效时间为2.7-4.6个月。
- 中位缓解持续时间:边缘区淋巴瘤未达到,滤泡性淋巴瘤11.1个月,小淋巴细胞淋巴瘤18.3个月。
- 中位无进展生存期:边缘区淋巴瘤未达到,滤泡性淋巴瘤10.6个月,小淋巴细胞淋巴瘤20.9个月。
关键数值与推荐
- 至少发生一次≥3级治疗中出现的不良事件的患者占53.4%。
- 32例(15.4%)患者因治疗中出现的不良事件停用Umbralisib。
- 31例(14.9%)患者因治疗相关不良事件停药。
- 发生率≥10%的≥3级治疗中出现的不良事件:中性粒细胞减少(11.5%)和腹泻(10.1%)。
- ≥3级丙氨酸氨基转移酶/天冬氨酸氨基转移酶升高分别发生于6.7%/7.2%的患者。
临床怎么用
- Umbralisib可作为经多线治疗(含抗CD20方案)失败的复发或难治性惰性淋巴瘤患者的治疗选择之一。
- 治疗期间需监测中性粒细胞减少、腹泻和肝酶升高等≥3级不良事件。
- 因不良事件停药率约15%,需权衡持续用药的获益与毒性管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kδ/casein kinase-1ε, exhibits improved selectivity for PI3Kδ compared with other PI3K inhibitors. This phase IIb trial was designed to evaluate the efficacy and safety of umbralisib in patients with R/R iNHL. PATIENTS AND METHODS: In this multicohort, open-label, phase IIb study, 208 patients with R/R marginal zone, follicular, or small lymphocytic lymphoma (MZL, FL, or SLL) unresponsive to prior treatments (≥ 1 MZL; ≥ 2 FL/SLL), including ≥ 1 anti-CD20-based therapy, were administered umbralisib 800 mg orally once daily until disease progression, unacceptable toxicity, or study withdrawal. Primary end point is overall response rate; secondary end points include time to response, duration of response, progression-free survival, and safety. RESULTS: The median follow-up is 27.7 months (efficacy) and 21.4 months (safety). The overall response rate was 47.1%, and tumor reduction occurred in 86.4% of patients. The median time to response was 2.7-4.6 months. The median duration of response was not reached for MZL, 11.1 months for FL, and 18.3 months for SLL. Median progression-free survival was not reached for MZL, 10.6 months for FL, and 20.9 months for SLL. At least one grade ≥ 3 treatment-emergent adverse event (TEAE) was reported in 53.4% of patients. TEAEs led to umbralisib discontinuation in 32 patients (15.4%). A total of 31 patients (14.9%) discontinued because of a treatment-related adverse event. Grade ≥ 3 TEAEs reported in ≥ 10% of patients: neutropenia (11.5%) and diarrhea (10.1%). Increased ALT/AST (grade ≥ 3) occurred in 6.7%/7.2% of patients. CONCLUSION: Umbralisib achieved meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event-related discontinuations.
引用
- Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021. PMID: 33683917. doi:10.1200/JCO.20.03433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。